Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1789]
In the citing paper
“Although pancreatic adverse events are difficult to completely rule out, an assessment by the FDA and the EMA concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data (77).”
From Safety of Semaglutide (2021) · cites this paper as [77]
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Cited by
Items 101–200 of 509
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“In a recent publication on the New England Journal of Medicine reporting the FDA and EMA joint assessment on pancreatic safety of incretin-based drugs [97], it is clearly spelled out that: “ .”
BackgroundJeepipalli, S. P. K., Du, B., Sabitaliyevich, U. Y., & Xu, B. (2020) · Food Chemistry · doi:10.1016/j.foodchem.2020.126474 · Cited by 65
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204.pub2 · Cited by 63
NREU, B., DICEMBRINI, I., TINTI, F., MANNUCCI, E., & MONAMI, M. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03219-8 · Cited by 63
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
Zhou, M., Mok, M. T. S., Sun, H., Chan, A. W. H., Huang, Y., Cheng, A. S. L., & Xu, G. (2017) · Oncogene · doi:10.1038/onc.2017.38 · Cited by 64
Wang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62
“For this reason, we conducted a systematic review and meta-analysis of observational studies [23–34] to assess the real-world incidence of AP associated with the use of IBTs.”
BackgroundMethodInfluentialCefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
“The FDA and the European Medicines Agency (EMA) carefully scrutinized preclinical and clinical data on this topic and recently came to a similar conclusion that no changes in recommendations are necessary until more firm data are available (128).”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis
Koehler, J. A., Baggio, L. L., Cao, X., Abdulla, T., Campbell, J. E., Secher, T., Jelsing, J., Larsen, B., & Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-0883 · Cited by 62
“An unresolved question is whether the small increase in serum levels of lipase, and to a lesser extent, amylase, observed in some patients treated with GLP-1R agonists (3) reflects the actions of these agents to increase pancreatic protein synthesis.”
BackgroundInfluentialGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
Kawakita, E., Koya, D., & Kanasaki, K. (2021) · Cancers · doi:10.3390/cancers13092191 · Cited by 69
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Huang, J., Jia, Y., Sun, S., & Meng, L. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00447-w · Cited by 66
“This was also the conclusion of a recent assessment by the US FDA and the European Medicines Agency, who further commented that while data provide reassurance, pancreatitis will continue to be considered a risk associated with incretin-based therapies until more data are available [26].”
ResultMüllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
“In 2014, the FDA and EMA concluded that assertions of a causal link between incretin use and pancreatic pathology were inconsistent with current data [79].”
BackgroundChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
“Pancreatic Events Acute pancreatitis and pancreatic cancer have been a concern of incretin-medications as a class.(67) No clear signal linking incretin-based therapies and acute pancreatitis or pancreatic cancer has been identified, though the FDA and EMA have indicated that pancreatitis should be considered a risk wi…”
BackgroundPotential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 50
“Overall, there has not been a clear cause and effect relationship described between GLP-1 RAs and pancreatitis [76, 77].”
BackgroundAn Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Chon, S., & Gautier, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.2.99 · Cited by 66
“based drugs [85].”
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults
Wang, T., Hong, J.-L., Gower, E. W., Pate, V., Garg, S., Buse, J. B., & Stürmer, T. (2018) · Diabetes Care · doi:10.2337/dc17-2285 · Cited by 52
“Safety concerns regarding IBTs have focused on pancreatitis (2), pancreatic cancer (3), medullary thyroid cancer (1), and heart failure (4,5).”
BackgroundGlucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
“, GLP-1 RAs and dipeptidyl peptidase 4 inhibitors) and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data’ [43].”
BackgroundTerauchi, Y., Satoi, Y., Takeuchi, M., & Imaoka, T. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0147 · Cited by 50
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 47
“…about incretin therapy increasing the risk of developing pancreatitis and pancreatic cancer, recent review of pre-clinical and clinical studies has not borne this hypothesis out, and the FDA and EMA have provided reassurance for the clinical and research use of these agents (Egan et al., 2014).”
BackgroundCombination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 56
“Although preclinical studies suggest associations between incretin-based therapy and pancreatitis or pancreatic cancer, retrospective observational trials have not confirmed this association nor have the FDA and EMA reviews of the available data identified any causal association, as discussed in case 1 [98].”
BackgroundAn Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
Liu, Y., Zhang, X., Chai, S., Zhao, X., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1534365 · Cited by 47
R. Drab, S. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 47
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“cases of acute pancreatitis in the active treatment groups compared with placebo groups.[75,76] The development of treatment-induced antidrug antibodies is always a concern with peptide and protein drugs, but”
BackgroundJensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Mittermayer, F., Caveney, E., De Oliveira, C., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399810666141224121927 · Cited by 47
Gurney, K., MacConell, L., Malloy, J., Zhou, M., & Kolterman, O. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s77290 · Cited by 45
“Recently, the FDA and European Medicines Agency conducted parallel assessments of the pancreatic safety of incretin-based drugs (based on nonclinical toxicology studies, clinical trial data, and epidemiological data) and did not find data consistent with previous reports of a causal association between incretinbased d…”
Schott, G., Martinez, Y. V., de Silva, R. E. E., Guiteras, A. R., Vögele, A., Reeves, D., Kunnamo, I., Marttila-Vaara, M., & Sönnichsen, A. C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0571-8 · Cited by 51
“Food and Drug Administration (FDA) and the European Medicines Agency (EMA) reported that there are still some uncertainties with respect to long-term pancreatic safety with DPP-4 inhibitors and evaluation of these outcomes is ongoing [63].”
BackgroundMayfield, C. K., Mont, M. A., Lieberman, J. R., & Heckmann, N. D. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.07.017 · Cited by 47
Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0321-6 · Cited by 47
“Separate independent reviews conducted by the US FDA and the EMA concluded that assertions regarding a causal relationship between these incretinbased drugs and pancreatitis or pancreatic cancer were inconsistent with the available data [65].”
BackgroundResultMontilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 49
“Later, the publication of two large cardiovascular outcome DPP-Is trials [13,22] and epidemiological data [23] stifled the debate; a 2014 joint Food and Drug Administration (FDA)eEuropean Medicines Agency (EMA) assessment concluded with a low-risk [24] but suggested continuous capture of data.”
BackgroundStoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 48
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 47
“However, post-marketing reports have suggested severe arthralgias and acute pancreatitis with the use of these inhibitors [30].”
BackgroundDulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 49
Mathieu, C., Kozlovski, P., Novartis Pharma AG, B., Paldánius, P. M., Novartis Pharma AG, B., Foley, J. E., Modgill, V., Novartis Pharma AG, B., Evans, M., Șerban, C. I., et al. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.68 · Cited by 48
National Trends in Diabetes Medication Use in the United States: 2008 to 2015
Raval, A. D., & Vyas, A. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018815048 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Although not all the above adverse effects related to GLP-1R agonists treatment have been supported by recent evidence [142,143], further research and rigorous clinical trials examining the incidence of these events are still needed.”
BackgroundLiraglutide: A Review of Its Use in the Management of Obesity
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0408-8 · Cited by 48
“tential risk of relatively rare cases of pancreatitis and pancreatic and thyroid cancer with long-term use of GLP-1 receptor agonists, including liraglutide, and DPP-4 inhibitors in patients with type 2 diabetes, the evidence remains equivocal [47].”
BackgroundUse of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
Knapen, L. M., de Jong, R. G. P. J., Driessen, J. H. M., Keulemans, Y. C. A., van Erp, N. P., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12833 · Cited by 46
“13 18 – 20 Furthermore, in contrast to the risk of acute pancreatitis, the risk of chronic pancreatitis with incretin use has not been investigated in an observational setting.”
Wewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 40
“Our findings are consistent with the recently published joint statement (Egan et al., 2014) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who, after considering all available animal (18,000 animals) and clinical data (41,000 participants, including 28,000 exposed to GLP-1 [incre…”
BackgroundResultInfluentialViggers, R., Jensen, M. H., Laursen, H. V. B., Drewes, A. M., Vestergaard, P., & Olesen, S. S. (2021) · Diabetes Care · doi:10.2337/dc21-0333 · Cited by 47
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“Both FDA and EMA have independently reviewed large-scale studies evaluating the risk of pancreatitis and pancreatic cancer without finding a causal association [103].”
BackgroundGLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
What have we learnt from “real world” data, observational studies and meta‐analyses
Chatterjee, S., Davies, M. J., & Khunti, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13178 · Cited by 43
“toxicology studies in rodents and non-rodents as well as clinical safety databases.(45) The FDA evaluation examined 41 000 participants TABLE 3 (Continued)”
BackgroundAlogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0385-y · Cited by 45
“pancreatitis or pancreatic cancer, and that while the totality of data provides reassurance, pancreatitis will continue to be considered a risk associated with these agents until more data are available [82].”
BackgroundResultComparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE
Cornell, S. A. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.11.005 · Cited by 46
Divino, V., DeKoven, M., Hallinan, S., Varol, N., Wirta, S. B., Lee, W. C., & Reaney, M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0087-6 · Cited by 41
“While concerns of an association with pancreatic disease exist, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have agreed that a causal association is inconsistent with the current data [3].”
Gautier, J.-F., Martinez, L., Penfornis, A., Eschwège, E., Charpentier, G., Huret, B., Madani, S., & Gourdy, P. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0245-x · Cited by 40
“and in the media, are inconsistent with the current data [37].”
ResultManagement Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review
Cehic, M. G., Nundlall, N., Greenfield, J. R., & Macdonald, P. S. (2018) · Journal of Transplantation · doi:10.1155/2018/1025893 · Cited by 43
“Medicines Agency (EMA) regulatory study [109] concluded there was no increased risk of acute pancreatitis related to”
BackgroundLamos, E. M., Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1626823 · Cited by 47
“inhibitor therapy and pancreatic cancer [40].”
BackgroundIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
“There is a small increase in pancreatitis with GLP-1 RAs from available randomized controlled trial data, but causality is yet to be proved (20).”
BackgroundIncretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 41
The European Medicines Agency's approval of new medicines for type 2 diabetes
BLIND, E., Janssen, H., Dunder, K., & de Graeff, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13349 · Cited by 49
“on pancreatic safety), confirming regulatory data obtained earlier.(23) For four of the authorized GLP-1 receptor agonists, CVOTs have been completed, and in two cases (liraglutide and semaglutide) these showed a reduction of at least some components of MACE in selected populations with T2D and a high CV risk compared…”
BackgroundSelf-citationCao, M., Pan, C., Tian, Y., Wang, L., Zhao, Z., & Zhu, B. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01556-2 · Cited by 40
“Thus, the FDA and the European Medicines Agency did not find a causal association between incretin-based drugs and pancreatitis or pancreatic cancer in their review of published data and recommended continued investigation of this safety signal [28].”
BackgroundManagement of Hyperglycemia in Type 2 Diabetes, 2015: A Patient- Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., & Wender, R. C. (2015) · Cited by 44
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“assessed by the FDA and the EMA in 2014.[117] The meta-analyses by Monami et al.”
BackgroundAlbiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0370-5 · Cited by 39
“receptor agonists and DPP-4 inhibitors) and pancreatitis or pancreatic cancer were inconsistent with the available data [53].”
BackgroundResultWagner, L., Kaestner, F., Wolf, R., Stiller, H., Heiser, U. F., Manhart, S., Hoffmann, T., Rahfeld, J., Demuth, H., Rothermundt, M., et al. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.02.007 · Cited by 41
“Concerns regarding increased risks of cancer, depression and infection have only been confirmed with infection (Egan et al., 2014).”
BackgroundType 2 Diabetes Medication Review
Sterrett, J., Bragg, S. W., & Weart, C. W. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.01.019 · Cited by 43
“Additional data from the ongoing required safety/CV studies would hopefully add to the current data and more conclusively determine the degree of causation.(52)”
BackgroundIncretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 39
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
“Extensive data analyzes by the US FDA and EMA did not reach a final conclusion regarding such a causal relationship, but both agencies agreed that the current knowledge is adequately reflected in the product labeling.[26] Long-term outcome trials have been completed and published for three DPP-4 inhibitors (saxaglipti…”
BackgroundCase Reports of Pre-clinical Replication Studies in Metabolism and Diabetes
von Herrath, M., Pagni, P. P., Grove, K., Christoffersson, G., Tang-Christensen, M., Karlsen, A. E., & Petersen, J. S. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.004 · Cited by 39
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
“Concerns with respect to pancreatitis an d pancreatic cancer have been assessed by the EMA and FDA, who have not found a significant signa l i pooled data [62], but use in patients with either of these conditions clearly is not advi sable.”
Cardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
“with these drugs until more data are available [61,62].”
BackgroundBenefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 43
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Ja’arah, D., Al Zoubi, M. S., Abdelhady, G., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 35
Nauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
“It is reassuring that no changes have been observed in various nondiabetic and diabetic animal models during long-term exposure to GLP1–based therapeutics (18).”
BackgroundShah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“30 In rodents, GLP-1RA exposure is associated with thyroid C-cell tumor development.”
Dotan, I., Rudman, Y., Turjeman, ., Akirov, A., Steinmetz, T., Calvarysky, B., & Diker‐Cohen, T. (2024) · Transplantation · doi:10.1097/tp.0000000000004945 · Cited by 37
“An association or causality between the use of GLP1-RAs and pancreatitis or pancreatic cancer has not been established, 41,42 yet monitoring and reporting are ongoing.”
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s126763 · Cited by 36
“Although long-term studies of GLP-1RAs do not indicate an increased risk of pancreatitis, regulatory agencies continue to monitor signals for the GLP-1-based therapies with respect to pancreatic safety.(34) There are important limitations to the studies reviewed which limit conclusions that can be drawn about relative…”
BackgroundSasaki, S., Miyatsuka, T., Matsuoka, T., Takahara, M., Yamamoto, Y., Yasuda, T., Kaneto, H., Fujitani, Y., German, M. S., Akiyama, H., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3728-z · Cited by 37
Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong, D., Xie, J., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00407-3 · Cited by 38
“In the past few years, many drugs related to GLP-1 have been approved by the Food and Drug Administration for the treatment of diabetes [12], such as the GLP-1R agonists liraglutide, exenatide, and exenatide extended-release, which have a long half-life and stability, and inhibitors of dipeptidyl peptidase 4 (DDP-IV),…”
BackgroundExenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study
Liang, C., Bertoia, M. L., Ding, Y., Clifford, C. R., Qiao, Q., Gagne, J. J., & Dore, D. D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13597 · Cited by 35
“and dipeptidyl peptidase-4 (DPP-4) inhibitors may increase the risk of pancreatic and thyroid cancer.(1) Many observational studies have”
BackgroundSafety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial
Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C., Craciun, A., Pall, D., et al. (2025) · Obesity · doi:10.1002/oby.24222 · Cited by 35
“The FDA and EMA noted no association between incretin-based drugs prescribed for diabetes and pancreatitis [24].”
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“Nevertheless, based on recent scrutiny of the collective evidence from preclinical and clinical studies, the regulatory authorities have reported that the available data are not consistent with a causal association between incretinbased agents and pancreatic safety issues [80].”
BackgroundIncretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know
Forsmark, C. E. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.009 · Cited by 36
Riederer, A., Zini, E., Salesov, E., Fracassi, F., Padrutt, I., Macha, K., Stöckle, T. M., Lutz, T. A., & Reusch, C. E. (2016) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13817 · Cited by 35
“The Food and Drug Administration and the European Medicines Agency recently stated that it is currently unclear whether there is a causal relationship between incretin-based drugs and pancreatitis.(27) To our knowledge, a possible association between incretin-based treatment and pancreatitis in cats has not been inves…”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 34
“…2009 found that while both the FDA and EMA assert that concerns of a causal association between incretin-based drugs and pancreatic cancer are inconsistent with current data, thyroid and pancreatic cancer were reported more frequently in patients treated with exenatide than with rosiglitazone [79].”
BackgroundSingh, A. K., Gangopadhyay, K. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1736041 · Cited by 33
Review of Associations Between Type 2 Diabetes and Cancer
Bonagiri, P. R., & Shubrook, J. H. (2020) · Clinical Diabetes · doi:10.2337/cd19-0077 · Cited by 33
Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin
Chouchane, K., Zenzo, G. D., Pitocco, D., Calabrese, L., & SIMONE, C. D. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03192-8 · Cited by 32
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
“In February 2014, FDA and EMA issued the aforementioned joint statement on the use of incretin-based treatment modalities and risk of pancreas pathology [40].”
BackgroundGenovese, S., Mannucci, E., & Ceriello, A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0499-6 · Cited by 33
“Data from RCTs do not indicate an increased risk for pancreatic cancer with these medicines, and this risk has not been specifically assessed in observational studies or meta-analyses, thus no firm conclusion can be drawn in this regards [64].”
BackgroundLinagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus
McKeage, K. (2014) · Drugs · doi:10.1007/s40265-014-0308-3 · Cited by 31
“This was also the conclusion of a recent assessment by the US FDA and the European Medicines Agency, who further commented that while data provides reassurance, pancreatitis will continue to be considered a risk associated with incretin-based therapies until more data are available [93].”
ResultLocalization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells
Augstein, P., Naselli, G., Loudovaris, T., Hawthorne, W. J., Campbell, P. T., Bandala‐Sanchez, E., Rogers, K. L., Heinke, P., Thomas, H. E., Kay, T. W. H., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.010 · Cited by 31
“[40] Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al.”
BackgroundInfluentialWang, H., Liu, Y., Tian, Q., Yang, J., Lu, R., Zhan, S., Haukka, J. K., & Hong, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13177 · Cited by 38
Hasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29
Forsmark, C. E., Vege, S. S., & Wilcox, C. M. (2017) · PubMed · doi:10.1056/nejmc1616177 · Cited by 29
Méndez‐Bailón, M., de Miguel-Yanes, J. M., Jiménez‐García, R., Hernández‐Barrera, V., Pérez-Farinós, N., & López‐de‐Andrés, A. (2014) · Pancreatology · doi:10.1016/j.pan.2014.11.004 · Cited by 35
Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Saisho, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.24 · Cited by 31
“After marketing of incretin-based drugs, cases of AP have been reported and the FDA has ordered a warning label (6,7).”
BackgroundYabe, D., Kuwata, H., Kaneko, M., Ito, C., Nishikino, R., Murorani, K., Kurose, T., & Seino, Y. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12381 · Cited by 28
Metadata
- Authors
- Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C.
- Affiliations
- European Medicines Agency (NL)
- Medical Products Agency (SE)
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-27
- Volume
- 370
- Issue
- 9
- Pages
- 794-797
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970905724
- Cited by
- 498
- References
- 4
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 45 · 2017: 53 · 2016: 66 · 2015: 81 · 2014: 65
- FWCI
- 71.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin-based drugs, drug safety assessment, FDA regulatory review, drug approval
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, European Union, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, United States, United States Food and Drug Administration, Drug Approval, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.